5697-56-3

• 常用中文名：甘珀酸
• 常用英文名：Carbenoxolone
• CAS号：5697-56-3
• 分子式：C₃₄H₅₀O₇
• 分子量：570.75700
• 相关类别： 原料药 消化系统用药 抗酸及胃黏膜保护药
• 发布时间：2018-07-18 10:44:11
• 更新时间：2024-01-02 18:22:09
• Carbenoxolone 是甘草次酸的半合成衍生物,由于其抗炎特性,被广泛用于消化不良和消化性溃疡的治疗。Carbenoxolone,半通道和间隙连接蛋白抑制剂,具有治疗慢性肝病的治疗潜力。Carbenoxolone 抑制 Aβ42 聚集,是抗 AD 治疗潜力的合适候选者。Carbenoxolone 是小分子 Pannexin1 (Panx1,是一种 ATP 释放通道) 抑制剂,通过调节第一个细胞外环来减弱 Panx1 通道活性。 Carbenoxolone 是 11β-羟基类固醇脱氢酶1型 (11β-HSD1) 抑制剂,可将无活性的糖皮质激素转化为活性形式。 Carbenoxolone 具有抗 DENV 感染的抗病毒活性,靶点针对病毒本身。

名称

• 中文名: 甘珀酸
• 英文名: Carbenoxolone
• 英文别名: CARBENOXOLONE(RG); bioral; CARBENOXOLONE [U; glycyrrhetinic acid hydrogen succinate; 2-Methylidene-2,3-dihydrofuran-3-one; biogastrone; Carbenoxolon; EINECS 227-174-2; MFCD00867458

物化性质

• 密度: 1.20
• 沸点: 687.4ºC at 760 mmHg
• 熔点: 291-294 °C
• 分子式: C₃₄H₅₀O₇
• 分子量: 570.75700
• 闪点: 211.6ºC
• 精确质量: 570.35600
• PSA: 117.97000
• LogP: 6.82830
• 外观性状: 白色结晶粉末
• 储存条件:

  避光，阴凉干燥处，密封保存

• 稳定性:

  常温常压下稳定，具有抗菌、抗肿瘤及肾上腺皮质激素样作用，可制成抗炎抗过敏制剂，用于治疗风湿性关节炎、气喘，甘草次酸是经典的抗炎药物，将其应用于化妆品中可调节皮肤的免疫功能，增强皮肤的抗病能力，消除炎症、预防过敏。

• 分子结构:

  1、 摩尔折射率：154.18

  2、 摩尔体积（m³/mol）：475.4

  3、 等张比容（90.2K）：1273.2

  4、 表面张力（dyne/cm）：51.4

  5、 极化率（10 ^-24cm ³）：61.12

• 计算化学:

  1、 疏水参数计算参考值（XlogP）：6.4

  2、 氢键供体数量：2

  3、 氢键受体数量：7

  4、 可旋转化学键数量：6

  5、 互变异构体数量：5

  6、 拓扑分子极性表面积（ TPSA ）： 118 7、 重原子数量：41

  8、 表面电荷：0

  9、 复杂度：1200

  10、 同位素原子数量：0

  11、 确定原子立构中心数量：9

  12、 不确定原子立构中心数量：0

  13、 确定化学键立构中心数量：0

  14、 不确定化学键立构中心数量：0

  15、 共价键单元数量：1

生物活性

• 描述: Carbenoxolone 是甘草次酸的半合成衍生物,由于其抗炎特性,被广泛用于消化不良和消化性溃疡的治疗。Carbenoxolone,半通道和间隙连接蛋白抑制剂,具有治疗慢性肝病的治疗潜力。Carbenoxolone 抑制 Aβ42 聚集,是抗 AD 治疗潜力的合适候选者。Carbenoxolone 是小分子 Pannexin1 (Panx1,是一种 ATP 释放通道) 抑制剂,通过调节第一个细胞外环来减弱 Panx1 通道活性。 Carbenoxolone 是 11β-羟基类固醇脱氢酶1型 (11β-HSD1) 抑制剂,可将无活性的糖皮质激素转化为活性形式。 Carbenoxolone 具有抗 DENV 感染的抗病毒活性,靶点针对病毒本身。
• 相关类别:
  研究领域 >> 感染
  研究领域 >> 炎症/免疫
  研究领域 >> 神经疾病
• 参考文献:

  [1]. Sharma S, et al. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone:Insight into mechanism of action. Neurochem Int. 2017 Sep;108:481-493.

  [2]. Crespo Yanguas S, et al. TAT-Gap19 and Carbenoxolone Alleviate Liver Fibrosis in Mice. Int J Mol Sci. 2018 Mar 12;19(3). pii: E817.

  [3]. Hirata K, et al. Formulation of carbenoxolone for delivery to the skin. Int J Pharm. 2013 May 20;448(2):360-5.

  [4]. Michalski K, et al. Carbenoxolone inhibits Pannexin1 channels through interactions in the first extracellular loop. J Gen Physiol. 2016 Feb;147(2):165-74.

  [5]. Kim J, et al. Protective effect of carbenoxolone on ER stress-induced cell death in hypothalamic neurons. Biochem Biophys Res Commun. 2015 Dec 25;468(4):793-9.

  [6]. Pu J, et al. Antiviral activity of Carbenoxolone disodium against dengue virus infection. J Med Virol. 2017 Apr;89(4):571-581

MSDS

Material Safety Data Sheet Section1. Identification of the substance Product Name: Carbenoxolone Synonyms: Section2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section3. Composition/information on ingredients. Ingredient name:Carbenoxolone CAS number:5697-56-3 Section4. First aid measures Skin contact:Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact:Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation:Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion:Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution:Wear approved mask/respirator Hand precaution:Wear suitable gloves/gauntlets Skin protection:Wear suitable protective clothing Eye protection:Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section7. Handling and storage Handling:This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels, refrigerated. Storage: Section8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section9. Physical and chemical properties Appearance:Not specified Boiling point:No data No data Melting point: Flash point:No data Density:No data Molecular formula:C34H50O7 Molecular weight:570.8 Section10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide. Section11. Toxicological information No data. Section12. Ecological information No data. Section13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section14. Transportation information Non-harzardous for air and ground transportation. Section15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313. SECTION 16 - ADDITIONAL INFORMATION N/A

毒性和生态

毒理学数据: 1、急性毒性： 小鼠口服LD50：2450mg/kg，毒性作用的描述没有报告除此以外的其他致死剂量值。 生态学数据: 燃烧产生刺激烟雾;药物副作用:肌肉无力,软弱无力,麻痹,瘫痪 CHEMICAL IDENTIFICATION RTECS NUMBER : RK0200000 CHEMICAL NAME : Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-, hydrogen succinate CAS REGISTRY NUMBER : 5697-56-3 LAST UPDATED : 199712 DATA ITEMS CITED : 10 MOLECULAR FORMULA : C34-H50-O7 MOLECULAR WEIGHT : 570.84 WISWESSER LINE NOTATION : L F6 E6 B666 CV DUTJ A1 HVQ H1 K1 N1 O1 S1 S1 TOV2VQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Human - man DOSE/DURATION : 120 mg/kg/56D-I TOXIC EFFECTS : Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - muscle weakness REFERENCE : BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 2,150,1976 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2450 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 19,323,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 128 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 19,323,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 1720 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 19,323,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1400 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4224327 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 290 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4363816 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 1060 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 19,323,1980 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : 371 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 19,323,1980 ** REPRODUCTIVE DATA ** TYPE OF TEST : TDLo - Lowest published toxic dose ROUTE OF EXPOSURE : Subcutaneous DOSE : 1313 mg/kg SEX/DURATION : female 1-21 day(s) after conception TOXIC EFFECTS : Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - biochemical and metabolic REFERENCE : DBTGAJ Diabetologia. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.1- 1965- Volume(issue)/page/year: 39,1299,1996

安全

• 危害码 (欧洲): Xi
• 风险声明 (欧洲): R36/37/38:Irritating to eyes, respiratory system and skin .
• 安全声明 (欧洲): S26-S36-S37/39
• WGK德国: 3
• 海关编码: 2938909030

海关

海关编码	2938909030